<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03472053</url>
  </required_header>
  <id_info>
    <org_study_id>BIO-NSCLC-001</org_study_id>
    <nct_id>NCT03472053</nct_id>
  </id_info>
  <brief_title>A Study of BIO-11006 in the Treatment of Advanced Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Randomized Study of the Safety and Efficacy of BIO-11006 in Treatment of Advanced Non-Small Cell Lung Cancer in Patients Who Are Not Candidates for Curative Surgery and/or Radiation and Who Are Receiving Pemetrexed and Carboplatin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioMarck Pharmaceuticals, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioMarck Pharmaceuticals, Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 2 is a randomized study in advanced Non-Small Cell lung cancer patients to
      evaluate safety and efficacy of aerosolized BIO-11006 in conjunction with chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This randomized, open label, multicenter Phase 2 study is to evaluate safety and efficacy of
      BIO-11006 in Stage IIIB Non Small Cell Lung cancer (NSCLC) patients who are not candidates
      for curative surgery, radiation, or immunotherapy and who are also receiving Pemetrexed and
      Carboplatin as standard of care (SOC). This study will be conducted at ten clinical centers
      in India under an IND from US-FDA and an IND from Indian FDA.

      This is a parallel 2- Arm study in which a total of 60 patients will be randomized. One Arm
      of 30 subjects will receive aerosolized 125mg BIO-11006 BID using Pari eFlow nebulizer in
      conjunction with SOC chemotherapy (Pemetrexed plus Carboplatin). A second Arm of 30 subjects
      will receive only SOC chemotherapy (Pemetrexed plus Carboplatin). The treatment period will
      be three months and nine months survival follow up period (every three months).

      Primary efficacy endpoint will be Progression-free survival (PFS) in patients who receive
      BIO-11006 plus SOC compared to those who receive SOC alone. The secondary efficacy endpoints
      will include: a. Response rate at three months (4 cycles) per RECIST V1.1; (b) overall
      survival; and (c) patient body weight maintenance.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will be randomized in 1:1 ratio to either BIO-11006 plus Standard of Care (intervention) or Standard of Care (Pemetrexed plus Carboplatin) (intervention).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>12 months</time_frame>
    <description>Survival period of patients in both arms of the study is measured in absence of tumor progression.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body weight</measure>
    <time_frame>3 and12 months</time_frame>
    <description>Maintenance of patient's body weight in kilograms measured at three month and at 12 month to assess possible disease related cachexia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>3 months</time_frame>
    <description>Treatment-emergent adverse events including headache, bronchitis, dyspnea, cough, pyrexia, chest discomfort and liver function will be evaluated by the institutional review board.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Non Small Cell Lung Cancer Stage IIIB</condition>
  <arm_group>
    <arm_group_label>BIO-11006 plus standard of care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aerosolized BIO-11006 (125mg BID) plus standard of care (Pemetrexed plus Carboplatin) is administered for three months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pemetrexed (500 mg/meter square) and Carboplatin (AUC6, Calvert's Formula) is administered every three weeks for three months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIO-11006 plus standard of care</intervention_name>
    <description>BIO-11006 is administered 125mg BID plus standard of care.</description>
    <arm_group_label>BIO-11006 plus standard of care</arm_group_label>
    <other_name>Active drug plus standard of care</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <description>Pemetrexed (500 mg/meter square) and Carboplatin (AUC6, Calvert's formula) are administered every three weeks for three months.</description>
    <arm_group_label>Standard of Care</arm_group_label>
    <other_name>Active comparator</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients who are physically able to self administer drug by nebulizer;

          2. Measurable disease per RECIST Version 1.1;

          3. Female patients of child bearing age must have a negative pregnancy test;

          4. ECOG 0-2;

          5. Written informed consent;

        Exclusion Criteria:

          1. Candidates for curative surgery and/or radiation therapy;

          2. Baseline ANC&lt;2000 cells/mm cube; platelet count &lt;100,000 cells/mm cube

          3. Creatinine clearance &lt;45 mL/min;

          4. Billirubin &gt;2 x the upper limit of normal

          5. Known history of HIV, hepatitis B, hepatitis C or tuberculosis;

          6. Current pneumonia or idiopathic pulmonary fibrosis;

          7. Hypersensitivity to test drug, pemetrexed, or carboplatin.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Devesh Verma, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Cliantha Research, India</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brian Dickson, MD</last_name>
    <phone>919-607-8490</phone>
    <email>bdickson@biomarck.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Indu Parikh, PhD</last_name>
    <phone>919-593-1274</phone>
    <email>iparikh@biomarck.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vardhman Mahavir Medical College &amp; Hospital</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110029</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Neeraj Singh, MS</last_name>
      <phone>+91-880-048-8618</phone>
      <email>neerajdangwal11@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Satya P Kataria, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kaushal Kalra, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mukesh Nagar, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aadhar Health Institute</name>
      <address>
        <city>Hisar</city>
        <state>Hariyana</state>
        <zip>125005</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harish Sharma, MD</last_name>
      <phone>+91-989-653-9125</phone>
      <email>harishsharma72@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Coordinator</last_name>
      <phone>+91-701-819-6594</phone>
      <email>asankushshm@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Lovenish Goyal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HCG Manavata Cancer Center</name>
      <address>
        <city>Nashik</city>
        <state>Maharashtra</state>
        <zip>422004</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nishtha Paleja, MBBS</last_name>
      <phone>+91-982-325-8862</phone>
      <email>drnishthapaleja@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Rajnish Nagarkar, MSBSS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vijay Palwe, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Deenanath Mangeshkar Hospital &amp; Research Center</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411004</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A Asmita, BS</last_name>
      <phone>+91-996-008-4830</phone>
      <email>asmitaharne2412@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Chetan Deshmukh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Padmaj Kulkarni, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tata Memorial Hospital</name>
      <address>
        <city>Mumbai</city>
        <state>Maharastra</state>
        <zip>400012</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vijay Patil, MD</last_name>
      <phone>+91-986-938-2266</phone>
      <email>vijaypgi@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Coordinator</last_name>
      <phone>+91-983-394-4571</phone>
      <email>drsrushti25@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Amit Joshi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kumar Prabhash, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chirayu Cancer Hospital</name>
      <address>
        <city>Bhopal</city>
        <state>MP</state>
        <zip>462030</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hakimudin Malvi, MD</last_name>
      <phone>+91-942-567-2336</phone>
      <email>hakimmalvi@yahoo.co.in</email>
    </contact>
    <investigator>
      <last_name>Tarini P Sahoo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sparsh Hospitals and Critical Care</name>
      <address>
        <city>Bhubaneswar</city>
        <state>Odisa</state>
        <zip>751007</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Siddharth Mohanty, MS</last_name>
      <phone>+91-732-707-8993</phone>
      <email>sidharthmohanty74@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ghanashyam Biswas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bharat Das, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SMS Medical College &amp; Hospital</name>
      <address>
        <city>Jaipur</city>
        <state>Rajasthan</state>
        <zip>302016</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shivraj Sharma, MD</last_name>
      <phone>+91-141-400-7619</phone>
      <email>drsrs74@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Coordinator</last_name>
      <phone>+91-756-823-0335</phone>
      <email>mgargmm@rediffmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Narendra Khippal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shantanu Sharma, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sandeep Jasuja, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nehru Hospital &amp; Post Graduate Institute of Medical Education</name>
      <address>
        <city>Chandigarh</city>
        <zip>160012</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M Shashank, MS</last_name>
      <phone>+91-988-805-8173</phone>
      <email>ethicscare@ecrsindia.com</email>
    </contact>
    <investigator>
      <last_name>Navneet Singh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>D Behra, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>R Kapoor, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2018</study_first_submitted>
  <study_first_submitted_qc>March 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 21, 2018</study_first_posted>
  <last_update_submitted>March 14, 2018</last_update_submitted>
  <last_update_submitted_qc>March 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lung cancer</keyword>
  <keyword>non small cell</keyword>
  <keyword>metastasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

